Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients

American Journal of the Medical Sciences

Volumn 337, Issue 2, 2009, Pages 116-122

  Hsu, Heng Jung ^a   Wu, Mai Szu ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

End stage renal disease; ESRD; FGF23; Fibroblast growth factor 23; Hemodialysis; Left ventricular hypertrophy

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; UREA; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; ECHOGRAPHY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 61849155234     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181815498     Document Type: Article

References (39)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-S119. (Pubitemid 28527268)
2. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;42(6 suppl 5):A5-7, S1-S230.
3. Agodoa LY, Eggers PW. Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis 1995;25:119-133
4. Iseki K, Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996;50:1672-1675 (Pubitemid 26364274)
5. Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993;44:1086-1090 (Pubitemid 23316478)
6. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192
7. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-2767 (Pubitemid 33115424)
8. Silberberg JS, Barre PE, Prichard SS, et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290 (Pubitemid 19202488)
9. Foley RN, Parfrey PS, Harnett JD, et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995;5:2024-2031
10. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003;16:111-117 (Pubitemid 37356823)
11. Meeus F, Kourilsky O, Guerin AP, et al. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int Suppl 2000;76:S140-S147. (Pubitemid 30612814)
12. Ayus JC, Go AS, Valderrabano F, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. Kidney Int 2005;68:788-795 (Pubitemid 43323135)
13. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005;16:2778-2788
14. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218 (Pubitemid 39031360)
15. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 2004;65:1-14. (Pubitemid 38037486)
16. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-1946 (Pubitemid 38591047)
17. Engelmann GL, Dionne CA, Jaye MC. Acidic fibroblast growth factor and heart development. Role in myocyte proliferation and capillary angiogenesis. Circ Res 1993;72:7-19.
18. Kardami E, Detillieux K, Ma X, et al. Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 2007;12:267-277
19. Jiang ZS, Jeyaraman M, Wen GB, et al. High- but not low-molecular weight FGF-2 causes cardiac hypertrophy in vivo; possible involvement of cardiotrophin-1. J Mol Cell Cardiol 2007;42:222-233 (Pubitemid 44958615)
20. Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-1178 (Pubitemid 41623344)
21. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147-1154 (Pubitemid 34627872)
22. Lewis JF, Kuo LC, Nelson JG, et al. Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation 1984;70:425-431
23. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-618
24. Devereux RB, Koren MJ, de Simone G, et al. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 1993;14(suppl D):8-15 (Pubitemid 23233994)
25. Levin A, Thompson CR, Ethier J, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134 (Pubitemid 29318806)
26. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354 (Pubitemid 26075843)
27. Chang ST, Chen CC, Chen CL, et al. Changes of the cardiac architectures and functions for chronic hemodialysis patients with dry weight determined by echocardiography. Blood Purif 2004;22:351-359 (Pubitemid 39179221)
28. Kutlay S, Dincer I, Sengul S, et al. The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients. Am J Kidney Dis 2006;47:485-492 (Pubitemid 43255183)
29. Strozecki P, Adamowicz A, Nartowicz E, et al. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001;23:115-126 (Pubitemid 32207300)
30. Neves KR, Graciolli FG, dos Reis LM, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-2244
31. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
32. Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006;169:2161-2170 (Pubitemid 351181975)
33. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 2007;16:329-335 (Pubitemid 46944331)
34. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004;314:409-414 (Pubitemid 38084732)
35. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004;23:421-432 (Pubitemid 39576657)
36. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-568 (Pubitemid 38542505)
37. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-6123 (Pubitemid 43847540)
38. Li SA, Watanabe M, Yamada H, et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004;29:91-99 (Pubitemid 40260033)
39. Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton) 2007;12:500-509 (Pubitemid 47366641)